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INTRODUCTION
Although drug-eluting stents (DES) have dramatically
reduced the rate of restenosis, concerns about the risk of stent
thrombosis (ST) has been raise. ST remains as a major cause
of death after DES implantation (1).
Most ST cases were associated with discontinuation of
antiplatelet therapy. The discontinuation of antiplatelet med-
ication has been strongly associated with DES thrombosis
and is usually seen within two weeks after cessation of anti-
platelet treatment, but cases of late ST (LST) or very late ST
(VLST) with current antiplatelet medication will lead to a
debate on how long one should continue anti-platelet drug
therapy after DES implantation.
Here we report a case of VLST at 26 months after DES
implantation in a patient with current aspirin and clopido-
grel medication.
CASE REPORT
A 73-yr-old female presented to emergency room (ER) in
May 2004 with effort angina. She had a history of hyperten-
sion. She did not show any specific abnormalities on physi-
cal examination. The biochemical test results, including car-
diac enzymes, were all normal. Coronary angiography (CAG)
revealed a critical lesion in the mid-portion of left anterior
descending (LAD) artery (Fig. 1A). She underwent percuta-
neous coronary intervention (PCI) with one 3.0×33 mm
Sirolimus eluting CypherTM stent (Cordis, Johnson and John-
son, Miami, FL, U.S.A.) for the LAD lesion with acceptable
final angiographic results (Fig. 1B). She was discharged with
combined anti-platelet agents of aspirin 100 mg and clopi-
dogrel 75 mg, and had uneventful recovery. 
In July 2006, at 26 months after the first PCI, the patient
presented to ER with severe chest pain. At the point of time,
she did not stop aspirin and clopidogrel medications, nor
had any kind of specific medication history. Her electrocar-
diogram at ER showed 5 mm ST segment elevation with
tall T waves in precordial leads suggestive of acute anterior
wall myocardial infarction (Fig. 2). The peak level of crea-
tine kinase (CK) was 1,334 U/L, CK-MB was 75.4 U/L, and
troponin-I was 38.1 ng/mL. Transthoracic echocardiogra-
phy revealed anteroseptal wall akinesia and ejection fraction
45%. The patient received a loading dose of 600 mg of clopi-
dogrel and transferred to the cardiac catheterization labora-
tory. Emergent CAG revealed a thrombotic total occlusion of
the middle LAD (Fig. 3A). The occluded LAD was revascu-
larized successfully with balloon angioplasty (Fig. 3B).
Ultegra Rapid Platelet Function Assay (RPFA)-ASA and
Ultegra RPFA-P2Y12 (VerifyNowTM Assay
�, Accumetrics
Inc., San Diego, CA, U.S.A.) were performed to determine
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Very Late Stent Thrombosis after Drug-Eluting Stent Implantation
in a Patient without Aspirin and Clopidogrel Resistance
Very late stent thrombosis (VLST) after implantation of drug-eluting stent is rare,
but very fatal complication after percutaneous coronary intervention. We report a
case of VLST of a sirolimus-eluting Cypher
TM stent (Cordis, Johnson and Johnson)
presenting as acute ST elevation myocardial infarction at 26 months after deploy-
ment with continued combined dual antiplatelet medication of aspirin and clopido-
grel. The patient did not show anti-platelet resistance.
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aspirin and clopidogrel resistance. The blood sampling was
performed 2 weeks after coronary intervention. Aspirin resis-
tance was defined as an aspirin reaction units (ARU) ≥550.
Clopidogrel resistance was defined as the percent inhibition
of P2Y12 less than 20%. The patient’s ARU was 350 and
P2Y12 was 90%.
The patient was discharged uneventfully with triple com-
bined anti-platelet regimen of 100 mg aspirin, 75 mg clopi-
dogrel, and 200 mg cilostazol per day after aspirin and clopi-
dogrel resistance test, and has been asymptomatic during
the 6-month clinical follow-up.
DISCUSSION
Nowadays, the introduction of DES has rapidly and pro-
foundly affected the field of interventional cardiology, and
DES is used in a majority of intracoronary stenting proce-
dures. DES is successful in a majority of cases in preventing
restenosis for the first year following stent implantation.
Although DES has helped overcome the limitation of ins-
tent restenosis, a new problem that seems to be associated
with the use of DES is ST. ST is a rare, but fatal complica-
tion after DES implantation. The recently proposed ‘‘Academ-
ic Research Consortium’’ definitions were designed to stan-
dardize the diagnosis of ST (2). Acute ST was defined as ST
during PCI or within the following 24 hr, subacute ST as
between 1 and 30 days following PCI, LST as between 1
month and 1 yr following PCI, and VLST as more than 1 yr
following PCI. 
In treatment with DES, the rate of acute and subacute ST
seems to be similar to that of bare-metal stents (BMS); it
remains below 1% for BMS and DES. And the mechanisms
underlying the acute and subacute ST after BMS and DES
are very similar (3, 4). Ishikawa et al. reported that subacute
thrombosis did not increase after stenting with sirolimus
eluting CypherTM stent under combined antiplatelet therapy
even in patients with acute myocardial infarction (5).
However, in case of LST or VLST after DES implantation,
recent studies have highlighted the increased incidence and
potential adverse clinical significance compared with BMS.
In the BASKET-LATE study, the rates of LST was higher in
DES group (2.6% DES group vs. 1.3% BMS group) and
major adverse cardiac events due to LST were also higher in
DES group (4.9% DES group vs. 1.3% BMS group, respec-
tively) (6). In a meta-analysis of 9 trials involving 5,261 pate-
ints, increased rates of VLST were found both for SES (0.6%
Fig. 2. In July 2006, at 26 months after PCI, electrocardiogram at
emergency room showed 5 mm ST segment elevation with tall T
waves in precordial leads suggestive of acute anterior wall myocar-
dial infarction.
Fig. 1. Coronary angiography (CAG) revealed a critical lesion in the middle left anterior descending artery (A). After percutaneous coro-
nary intervention, CAG showed excellent final angiographic results (B). 
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vs. 0%, p=0.025) and PES (0.7% vs. 0.2%, p=0.028), com-
pared with BMS over 4 yr of follow-up (7). Similarly, a meta-
analysis of 14 trials on 4,958 patients, with follow-up rang-
ing up to 59 months, showed an increased rate of VLST with
SES (0.6% vs. 0.05%, p=0.02) (8).
The reasons for LST or VLST in the population treated
with DES remain incompletely understood. The presence of
endothelial dysfunction and delayed healing were often des-
cribed in cases of LST or VLST in DES-treated lesion (9).
The mechanism seems to be related to the delay in the heal-
ing process and also may be related with late hypersensitivi-
ty reaction and consequent inflammatory changes predispos-
ing to stent thrombosis even years after initial deployment.
These hypotheses are based upon histological characteriza-
tion of tissue responses in animal studies revealing arrest of
healing process and presence of inflammatory cells as a part
of this delayed healing. In addition to this phenomenon,
hypersensitivity reaction to the polymer and localized hyper-
sensitivity vasculitis within the stented segment could have
contributed to the adverse long-term clinical outcome.
Some clinical features such as premature discontinuation of
anti-platelet therapy, diabetes, lower ejection fraction, bifur-
cation lesions, and stent under-expansion have been identi-
fied as independent predictors of VLST (10-12).
In real world, most VLST cases are associated with discon-
tinuation of anti-platelet agent due to dental procedure or
non-cardiac surgery. LST or VLST usually occurs within days
to months after aspirin and clopidogrel discontinuation, and
appears more closely related to discontinuation of aspirin
(10, 11).
However, our patient did not have any of the risk factors
for VLST; most importantly, he was on current dual anti-
platelet therapy for 26 months after PCI and showed no anti-
platelet drug resistance by VerifyNowTM Assay
� system. A
mechanical problem such as an unrecognized edge dissection
or under-expansion of stent is unlikely as the time interval
was too long. In this case, long lesion was an independent
predictive factor of LST or VLST due to delayed endothelial-
ization.
Prolonged combined anti-platelet therapy is needed for
such patients at high risk of VLST, but the issue is how to
identify the high-risk patients. Perhaps the introduction of
new generation of DES with improved biocompatibility and
better healing may be one of the answers for the prevention
of VLST.
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